Neurology Today in 5

Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs

May 15, 2025

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several...

Microplastics in brain, salary gap in neurology, the neurology of space

May 1, 2025

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles finding microplastics in the brain postmortem linked to dementia, the salary gap between men and women neurologies, and neurologists studying the impact of microgravity on the...

Impact of high-dose Vitamin D on MS relapse, the role of AI in neurology education, and a 4D animal model that shows precursors of MS lesions before they appear.

Apr 17, 2025

In this episodeof Neurology Today in 5, Neurology Today editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a large trial that found high-dose Vitamin D reduced MRI evidence of disease activity in patients with clinically isolated syndrome or early relapsing MS; an animal brain map, revealing changes in...

New approved drug for neurofibromatosis 1 with plexiform neurofibromas, multidisciplinary clinics in neurology, impact of cuts to DEI research grants

Apr 3, 2025

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the newly approved drug for neurofibromatosis 1 with plexiform neuromas in adults, how neurology practices are integrating with multiple subspecialties, and the impact of federal cuts to DEI grants...

Impact of NIH cuts on neurology research, response to ACP’s guideline on migraine, an updated position on seizures, driver licensure, and medical reporting

Mar 20, 2025

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the impact of NIH cuts to indirect research costs, response to a new guideline on migraine prevention from ACP, and an updated position statement from the AAN on seizures, driver licensures, and medical...